Objectives/Hypothesis: Males with isolated hypogonadotropic hypogonadism (IHH) fail to undergo normal sexual development, including the lack of masculinization of the larynx. The objective of this study was to measure the mean vocal fundamental frequency (MF 0 ) in IHH patients and determine the impact of androgen treatment. An additional aim was to compare the MF 0 between IHH patients and controls. Study Design: Prospective observational study. Methods: Twenty-four patients with IHH were identified along with 30 normal males and females. Voice recordings were obtained on all subjects. Androgen therapy was administered to the IHH patients. The MF 0 and serum sex hormone levels were measured before treatment and at intervals during therapy. These results were compared with the pretreatment data within the IHH group. Voice parameters were also compared between the pre-and posttreatment IHH patients and the normal males and females. Results: The MF 0 in untreated IHH patients was 229 ؎ 41 Hz. This was intermediate between the normal male (150 ؎ 22 Hz, P < .001) and normal female patients (256 ؎ 29 Hz, P < .01). After treatment, the MF 0 in the IHH group decreased to 173 ؎ 30 Hz (P < .0001); indeed, their posttreatment MF 0 approached that of normal males (P < .08). Serum hormone levels responded to the injected testosterone, but these levels did not directly correlate with MF 0 . Conclusions: MF 0 in IHH patients is intermediate between normal male and female levels. After treatment with testosterone, these values approach the range of normal males. This prospective study details the impact of androgens on the larynx and vocal function in patients with IHH.
INTRODUCTION
The differing characteristics of male and female voices are easily recognized, particularly those changes that occur around the time of puberty. Normal sexual development at this time is characterized by maturation of the genitals, the appearance of secondary sexual characteristics, as well as changes in mood and behavior. 1 In sexually mature males, the processes of spermatogenesis and sex steroid production are regulated by the pituitary gonadotropins luteinizing hormone (LH) and folliclestimulating hormone (FSH). In male idiopathic hypogonadotropic hypogonadism (IHH), gonadotropin secretion is impaired, resulting in a failure of sexual maturation.
The impact of sexual development on the voice is illustrated by the retention of feminine voice characteristics in boys who undergo orchiectomy before puberty. 2 Similarly, when androgenic agents are used in females, significant voice changes may occur. [3] [4] [5] These effects may also be seen in trained male singers with hypogonadism who are given testosterone replacement. In the latter case, significant vocal register and voice quality changes have been reported. 6 The primary objective of this study was to determine the mean fundamental voice frequency (MF 0 ) in a population of males with IHH and compare this with normal males and females. The secondary objective was to determine the impact of testosterone treatment by measuring the MF 0 over the course of androgen treatment.
MATERIALS AND METHODS

Subjects
In this prospectively acquired series, 24 patients with IHH were identified from the endocrinology clinic at our institution. Patients who had previously received androgenic agents or gonadotropin were excluded. The diagnosis of IHH followed the initial recognition of inappropriate sexual development, retardation of spontaneous puberty, or the lack of pubertal changes until 18 years old. The diagnosis was confirmed by determination of a serum testosterone concentration below normal expected levels as well as serum FSH and LH concentrations at or below normal levels. Computed tomography and magnetic resonance imaging of the brain were performed to evaluate for the presence of either pituitary or hypothalamic masses. The final confirmation required a normal smell test, an XY karyotype determination, and the presence of gonadotropin response to repetitive doses of gonadotropin releasing hormone. The 24 subjects were identified once these criteria were met. None had a positive family history of IHH. The patients were classified as Tanner stages I and II according to secondary sexual characteristics. The Tanner classification system is listed in Table I .
Thirty male and female adults who had completed normal pubertal maturation (Tanner stage V) were also studied as control groups for comparison with the male IHH patients. Every subject in the study was examined by an otolaryngologist to exclude any obvious pathology that could affect the voice. This included an otolaryngologic history and physical. Laryngoscopy was performed in all patients. Once identified for the study, the patients with IHH and the control groups underwent pretreatment voice recording and blood tests. Data were then gathered during and after treatment as outline below. All institutional guidelines for human subject data collection and study were followed.
Hormone Studies
Serum levels of total testosterone (TT) and estradiol (E2) were measured by immunochemoluminescence using a commercial kit (Bayer Corporation, Tarrytown, NY). Free testosterone (FT) was measured by radioimmunoassay (Diagnostic Product Corporation, Texas). Dehydroepiandrosterone sulfate (DHEAS) and sex hormone binding globulin (SHBG) were measured by immunochemoluminescence using a commercial kit, IMMULITE 1 (Diagnostic Product Corporation, Los Angeles, CA).
Hormone levels were first determined at baseline before the initiation of intramuscular injections of Sustanon 250 mg (Organon), a commercially available preparation of testosterone propionate 30 mg, testosterone phenpropionate 60 mg, testosterone isocaproate 60 mg, and testosterone decanoate 100 mg. After the initial injection, Sustanon was administered to IHH patients every 21 days for 3 months. The serum assays were repeated at 5, 10, and 90 days after the initiation of therapy. Hormone assessments at month 3 occurred 7 days after the last injection. All blood samples were collected from fasting patients and controls between 8:00 AM and 8:30 AM.
Voice Analysis
Acoustic parameters were determined by the Multi Dimensional Voice Program (model 5105, Ver. 2.3, Kay Elemetrics Corp, Lincoln Park, NJ). The voice samples were recorded by using a microphone (Shure, Dynamic cardioid microphone C606N, Niles, IL) placed 10 cm away and 45°below from the mouth. A midvowel segment on a sustained /a/, with a duration of 3 seconds at habitual loudness and pitch, was used. MF 0 for the voice samples were determined. The voice analyses of the male IHH patients were performed before the treatment and at the 5th and 10th days and 3rd months of the therapy, concurring with the days that the blood samples were taken.
Statistical Analysis
All the statistical analyses were performed by the SPSS 10.0 (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL) program. Descriptive statistics were shown as mean Ϯ SD. To investigate the differences between measurements, the repeated measurement procedure of the SPSS program was used; for the data that were not normally distributed the Friedman test was used. When considering the differences between two groups of data, the Wilcoxon signed rank test with Bonferroni correction was used. The male, female, and male IHH groups were compared by using the analysis of variance (ANOVA) module, with Bonferroni used as a post hoc test. When parametric assumptions were not appropriate, the Mann-Whitney U test with Bonferroni correction was used. For the correlations among the consecutive differences, the Pearson coefficient of correlation was used. A priori, a P value less than .05 was determined to be statistically significant.
The lower limits of detection for TT, estradiol (E2), FT, DHEAS, and SHBG were 10 ng/dL, 10 pg/mL, 0,18 pg/mL, 2 g/dL, 0.22 nmol/L, 13 nmol/L, respectively. The intra-assay and interassay coefficients of variation were 2.3% to 6.2% and 1.4% to 4.7% for TT, 2.3% to 3.0% and 1.5% to 2.9% for LH, 2.0% to 2.9% and 0.3% to 2.7% for FSH, 4.0% to 12.1% and 4.5% to 8.1% for E2, 3.7% to 6.2% and 7.3% to 9.7% for FT, 7.6% to 9.5% and 8.1% to 15.0% for DHEAS, 4.1% to 7.7% and 5.8% to 13.0% for SH.
RESULTS
There were 24 patients in the IHH group (mean age 20.6 years, range 19 -22). The normal male group had 30 subjects (mean age 20.9 years, range 20 -23) as did the normal female group (mean 21.1 years, range 20 -23). The MF 0 of groups is presented in Table II . The differences between the groups are statistically significant. (F ϭ 91.402; P Ͻ .001). The mean fundamental frequency of the IHH patients before treatment was intermediate between the male and female groups, being significantly lower than in the female subjects (P Ͻ .01) and higher than that of the male subjects (P Ͻ .001).
The hormone profile of the male IHH patients throughout the course of the study is summarized in Table  III . FT, TT, SHBG, and E2 levels all changed significantly during the study (respectively, 2 ϭ 57.301, P Ͻ .001; 2 ϭ 53.850, P Ͻ .001; 2 ϭ 45.650, P Ͻ .001; 2 ϭ 13.434, P Ͻ .01). The change seen in DHEAS levels did not reach statistically significance ( 2 ϭ 6.891, P ϭ .075). FT and TT showed a peak level at day 5, reaching a level that was significantly higher than the baseline values (respectively, z ϭ 4.286, P Ͻ .001; z ϭ 4.257, P Ͻ .001). At day 10, FT levels decreased significantly (respectively, z ϭ 4.257, P Ͻ .001; z ϭ 4.086, P Ͻ .001), although they remained significantly higher than the baseline values (respectively, z ϭ 4.286, P Ͻ .001; z ϭ 4.229, P Ͻ .001). The FT and TT levels did not change significantly from day 10 posttreatment levels through the third month (z ϭ 2.457, P ϭ .14; z ϭ 1.429, P ϭ .153). They did, however, again, remain higher than the baseline levels (z ϭ 3.331, P ϭ .01; z ϭ 4.114, P Ͻ .001). SHBG levels showed a significant decrease at day 5 (z ϭ 4.286, P Ͻ .001), day 10 (z ϭ 4.286, P Ͻ .001), and at the third month (z ϭ 2.972, P ϭ .003) when compared with baseline. E2 levels significantly increased at day 5 (z ϭ 2.776, P ϭ .006) and 10 (z ϭ 2.978, P ϭ .003), but the change at 3 months compared with baseline was not statistically significant (z ϭ 1.860, P ϭ .063).
Voice Analysis Results after Treatment
The mean F 0 of the male IHH subjects before the treatment was 229.33 Ϯ 41.29 Hz. This decreased to 218.13 Ϯ 30.81 at day 5 (F ϭ 6.713; P ϭ .016). The mean F 0 returned to the previously high values at day 10, at 226.17 Ϯ 38.29 Hz, showing no significant difference with baseline values (F ϭ 0.579, P ϭ .455). At the 3-month analysis, however, mean F 0 had decreased to 173.13 Ϯ 29.76 Hz, a statistically significant change from baseline values (F ϭ 82.664, P Ͻ .001). The progression of MF 0 results in the IHH group over time is displayed in Figure  1 . When compared with the normal female group, the mean F 0 of male IHH patients after 3 months of treatment was found to be significantly different (z ϭ 6.093, P Ͻ .001). Although the mean F 0 of the treated IHH patients was still higher than those of the control males, the difference between mean F 0 of normal male and IHH male groups was no longer statistically significant (z ϭ 1.723, P ϭ .085). These results are presented in bar graph format in Figure 2 . The mean differences of the F 0 between baseline measurements and the values at the day 5, 10, and the third month posttreatment are presented in Table IV . When the correlation between consecutive differences of MF 0 and consecutive differences of hormonal parameters was investigated, no significant correlation was detected.
DISCUSSION
Although habitual pitch and fundamental frequency of may be an indicator of vocal and sexual maturity, the genotype may not correspond to the perceived sex of the voice. In this study, it was determined that untreated male IHH patients have a mean F 0 intermediate between normal males and females. The difference between the MF 0 of normal male and IHH subjects objectively demonstrates the impact of endocrine abnormalities on voice parameters. This is further supported by the subsequent trend toward normalization the F 0 of IHH after androgen treatment as reported in this article.
Laryngeal maturation caused by androgen stimulation after puberty is a fundamental basis for the difference between the male and female voice, although the direct mechanisms for this are complex. Beckford et al. 7 investigated the effect of androgen stimulation to the laryngeal structures in a sheep model and reported that the thyroid cartilage demonstrated a greater response to male sex hormones than did the cricoid or arytenoid cartilages. In addition, it was found that larynges exposed to higher androgen levels tended to have a more acute thyroid angle. Specific anatomic measurements, such as distances between key landmarks of the larynx, are affected by androgen exposure. One example of this is the androgensensitive changes of the arytenoid cartilage. In Beckford's animal study, the distances between the vocal process and the base of the arytenoid increases with androgen stimulation, as does the distance from vocal process to the muscular process. The relative descent of the larynx, and subsequent enlargement of the vocal tract and resonance system with age and maturation, are additional factors affecting voice parameters. 8 Male versus female (P Ͻ .001) using two-tailed t-test). IHH ϭ isolated hypogonadotropic hypogonadism.
The presence of a difference between the F 0 of male IHH patients who have deficiency of testosterone and the F 0 of normal postpubertal female subjects may be explained by the development of some male genotypic characteristics despite the hormonal deficiency. Castrated individuals may have the external morphologic structure of a male with a lung capacity of 3.5 to 5 L and the muscular abdomen and pelvic girdle necessary to sustain a male voice and a male-type bony architecture of resonating chambers. 2 Changes in fundamental frequency are associated with androgen development and puberty characteristics. MF 0 is related to height, pubic hair stage (PH), testis volume, TT, and serum hormone binding globulin in boys during puberty. 9 Harries et al. 8 reported that although there was a correlation between testis volume and voice parameters, there was no relation between salivary testosterone concentrations and voice parameters of males at puberty. These investigators indicated that maximum vocal change occurred between stages G3 and G4 of the Tanner Classification. Vuorenkoski et al. 10 stated that the decrease in speaking fundamental frequency (SFF) occurred gradually as correlated with PH, and, although the mean lower frequency (LF) began to decrease earlier than mean SFF, the greatest change occurred later in mean LF (between PH 3 and 4) than in the mean SFF (between PH 2 and 3). 10 Although assessment of a single measurement of F 0 to determine the developmental stage of a patient has limited value, analysis of voice parameters over time, however, may contribute to evaluation of progress of a person's development. When testosterone was administered to male IHH patients in this study, a significant decrease in mean F 0 was noted at the fifth day following treatment, the same time that the highest levels of TT, FT, and E2 were present. As the hormone levels decreased at day 10, however, mean F 0 nearly returned to pretreatment levels. We postulate that changes in MF 0 occurring shortly after androgen administration may have been caused by the edema-forming effect of testosterone. The interfibrillar space of vocal folds is filled with a colloidal mass, consisting of polysaccharides and hyaluronic acid, and is capable of retaining a great amount of water. 5 Any factor changing the water binding capacity will have an effect on colloidal mass, potentially affecting F 0 . The transient decline at day 5 and subsequent increase at day 10 of mean F 0 is likely the result of from water shifts in the interfibrillary space.
At the end of the third month of treatment, the MF 0 of male IHH patients tended toward the MF 0 of the normal males whose secondary sex characteristics were well developed. It is known that testosterone replacement increases muscle mass in castrated animals. 11 Bhasin et al. 12 also showed that supraphysiologic doses of testosterone in normal men caused significant increases in the cross-sectional areas of the triceps and the quadriceps within 10 weeks. Androgen treatment induces myogenesis in the developing larynx of juvenile Xenopus laevis. 13 In an animal study with Xenopus laevis, it is shown that dehydrotestosterone (DHT) treatment converts the laryngeal muscle to a fast-twitch fiber type and results in hypertrophy of laryngeal muscle fibers, and androgen is more powerful determinant of muscle fiber size than innervation, 14 with all of these investigations illustrating the impact of androgens on the physiology of the vocal apparatus.
Talaat et al. 15 demonstrated in a murine model that laryngeal muscle changes were noticeable after 1 month of testosterone administration and that they became more evident after the second and third months of treatment. The changes were basically in the form of hypertrophy and hyperplasia, affecting mainly the medial part of thyroarytenoid muscle. The hypertrophy of the muscle fibers was irreversible at 2 months after discontinuation of the drug. On the basis if these previous reports and the findings of this article, it is postulated that the mechanism of change in mean F 0 of the IHH patients after testosterone administration is caused by an increase in the mass of vocal muscle.
CONCLUSION
To our knowledge, this is the first report to investigate voice parameters in a prospectively acquired series of IHH patients. We have shown that untreated males with IHH have a mean F 0 that is intermediate between normal males and females. After treatment with testosterone, the MF 0 changes to approximately that of normal males. Although the hormonal profile of this patient population reflects their underlying condition, there was no persistent correlation detected between mean F 0 and hormone levels over the course of treatment. The utility of voice parameters, such as the MF 0 , in the characterization of normal development may be the subject of future investigations. All patients receiving androgenic agents should be counseled regarding the likelihood for short-and longterm changes in vocal pitch. 
